Acceleron has brought in a top commercial exec from Bayer, Habib Dable, to lead the company as it aims to plan for a marketed product.

Mologen is seeking to raise €16 million to fund a suite of trials of its TLR9 agonist in patients with colorectal cancer, small cell lung cancer and HIV.

Belgium biotech argenx has seen its income double on the back of a strong year of deals, but has also seen fit to cut two former R&D pacts.

Struggling microcap GenVec has again been warned that it will be taken off the lucrative and respected Nasdaq exchange if it doesn’t get itself out of the…

A snapshot survey of biotech chiefs during the second quarter has shown that their confidence to be able to raise funds has doubled since Q1, but they are a…

Genmab is to increase expenses by 40% or more this year to position a CD3-CD20 bispecific antibody and a clutch of other programs to barrel into the clinic.

With Bristol-Myers Squibb suffering a shock setback last week when its blockbuster PD-1 drug failed in a key lung cancer trial, this could crack open the door…

Motif Bio has had its Nasdaq IPO hopes crushed by an unreceptive market, leaving the late-phase antibiotic player with a hole in its spending plans.

Financials